Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly presents study to better target patients for Alimta

Eli Lilly presents study to better target patients for Alimta

26th September 2007

Eli Lilly has presented a study to better target patients for its Alimta (pemetrexed for injection) in treatment of non-small cell lung cancer (NSCLC)

The clinical research shows that patients with NSCLC who are also classified as having a non-squamous histology would achieve statistically significant higher survival when treated in the second-line setting with Alimta when compared with using docetaxel.

Results were taking from a retrospective analysis of phase III data and were presented at the 14th European Cancer Conference (ECCO) in Barcelona.

Patrick Peterson, principal author of the analysis, confirmed the importance of histology when targeting patients.

“This particular analysis suggests that histology may play an important role in determining patients who are most likely to receive a larger treatment result from Alimta.”

Alimta was given the green light by both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) in 2004 for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy.

Earlier this week, Eli Lilly announced the submission of a centralised review application with the European Medicines Agency for Alimta (pemetrexed for injection) in combination with cisplatin as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.